Press Releases April 14, 2026 08:00 PM

Runway Growth Finance Corp. Announces Date for First Quarter 2026 Financial Results and Conference Call

Runway Growth Finance Corp. announces Q1 2026 earnings release and conference call date.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
RWAY

Runway Growth Finance Corp., a Nasdaq-listed specialty finance company providing flexible capital solutions to late- and growth-stage companies, will release its first quarter 2026 financial results after market close on May 7, 2026, followed by a conference call to discuss the results. The company is externally managed by an affiliate of BC Partners Advisors and regulated as a business development company.

Runway Growth Finance Corp. Announces Date for First Quarter 2026 Financial Results and Conference Call
RWAY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Runway Growth Finance Corp. will announce Q1 2026 financial results on May 7, 2026, after market close.
  • A conference call and webcast will be held on the same day to discuss the earnings results.
  • The company focuses on providing flexible capital solutions to late- and growth-stage companies as an alternative to equity financing.

MENLO PARK, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Nasdaq: RWAY), (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. Runway Growth will discuss its financial results on a conference call that day at 2:00 p.m. PT (5:00 p.m. ET).

To participate in the conference call or webcast, participants should register online at the Runway Growth Investor Relations website. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. The earnings call can also be accessed through the following links:

  • Conference Call
  • Webcast

A replay of the webcast will be available two hours after the call and archived on the same web page for 90 days.

About Runway Growth Finance Corp.

Runway Growth is a specialty finance company focused on providing flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity. Runway Growth is a closed-end investment fund that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. Runway Growth is externally managed by Runway Growth Capital LLC, an affiliate of BC Partners Advisors L.P., and led by industry veteran David Spreng. For more information, please visit www.runwaygrowth.com.

Forward-Looking Statements

Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in forward-looking statements as a result of a number of factors, including those described from time to time in Runway Growth’s filings with the Securities and Exchange Commission. Runway Growth undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

IR Contacts

Taylor Donahue, Prosek Partners, [email protected]

Thomas B. Raterman, Chief Financial Officer and Chief Operating Officer, [email protected]


Risks

  • Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially, including market conditions and regulatory risks.
  • As a business development company investing in growth-stage firms, Runway Growth is exposed to credit and investment risks tied to portfolio company performance.
  • The potential volatility in financial markets and economic conditions could impact demand for the company's financing solutions.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026